GGrantIndex
Sort

53,477 grants matching addiction

PTPRD phosphatase inhibitors for stimulant use disorders

$1,453,896
George R Uhl · University Of Maryland Baltimore · UG3 · FY2022 · DA

Boston Alcohol Research Collaboration on HIV/AIDS - Comorbidity Center (Boston ARCH CC)

$1,452,137
Michael D Stein · Boston University Medical Campus · P01 · FY2022 · AA

C57BI/6 Mouse Lines Expressing CRE-Recombinase in the Nervous System

$1,451,955
Ulrich Mueller · Scripps Research Institute, The · U01 · FY2007 · MH

DRUGS OF ABUSE - ROLE OF PROTEIN PHOSPHORYLATION

$1,451,548
Paul Greengard · Rockefeller University · P01 · FY2015 · DA

Novel Dopaminergic Stimulant Prodrug for the Treatment of Apathy in AD

$1,451,070
Sandeep Patil · Praxis Bioresearch, Llc · R44 · FY2021 · AG

Oncogenic mechanisms and molecular targets in lymphoma

$1,450,380
Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Clinical development of mechanism-based lymphoma therapies

$1,450,380
Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Molecular diagnosis and outcome prediction in lymphoma

$1,450,380
Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Functional genomic screens for molecular targets in cancer

$1,450,380
Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Alcohol Center for Translational Genetics (ACTG)

$1,450,160
Patricia H Janak · University Of California, San Francisco · P50 · FY2013 · AA

Coordinated medical treatment of opioid use disorder and infectious disease

$1,450,097
Sandra Ann Springer · Yale University · U01 · FY2019 · TR

DRUGS OF ABUSE--ROLE OF PROTEIN PHOSPHORYLATION

$1,448,938
Rockefeller University · P01 · FY2003 · DA

Center for Adaptive Treatment of Cigarette Addiction

$1,448,439
Jed E Rose · Duke University · P50 · FY2014 · DA

Development of Long-acting Cocaine Hydrolase as a Treatment for Cocaine Abuse

$1,448,427
Chang-Guo Zhan · University Of Kentucky · UH3 · FY2018 · DA

Methadone Dosing System (MDS)

$1,447,789
Patrik Schmidle · Cari Health, Inc. · U44 · FY2025 · DA

Development of a flagellin-cocaine conjugate vaccine

$1,447,504
Steven B. Mizel · Wake Forest University Health Sciences · RC2 · FY2010 · DA

The Ohio Valley Node of the Clinical Trials Network

$1,446,804
T John Winhusen · University Of Cincinnati · UG1 · FY2021 · DA

Profiling the human gut microbiome for potential analgesic bacterial therapies

$1,446,416
Philip Peter Strandwitz · Holobiome, Inc. · R34 · FY2021 · NS

Oncogenic mechanisms and molecular targets in lymphoma

$1,445,697
Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Molecular diagnosis and outcome prediction in lymphoma

$1,445,697
Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Clinical development of mechanism-based lymphoma therapies

$1,445,697
Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Functional genomic screens for molecular targets in cancer

$1,445,697
Louis Staudt · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Kentucky Women's Justice Community Overdose Innovation Network - Phase II

$1,445,488
Michele Staton · University Of Kentucky · RM1 · FY2025 · DA

Center on Intersystem Regulation by Drugs of Abuse

$1,445,477
Ellen M Unterwald · Temple Univ Of The Commonwealth · P30 · FY2020 · DA

Research Resource for Integrated Glycotechnology

$1,445,343
James H Prestegard · University Of Georgia · P41 · FY2009 · RR